Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

Giovanni Luca Gravina¹, Andrea Mancini¹, Patrizia Sanita¹, Flora Vitale¹, Francesco Marampon¹, Luca Ventura², Yosef Landesman³, Dilara McCauley³, Michael Kauffman³, Sharon Shacham³ and Claudio Festuccia¹*

Unfortunately, the original version of this article [1] contained a mistake. The word 'survivin' in the title was incorrectly included as 'surviving'. The title has been corrected above and in the original article.

Author details
¹Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L’Aquila, L’Aquila, Italy. ²Pathology Division, San, Salvatore Hospital, L’Aquila, Italy. ³Karyopharm Therapeutics, Newton, MA, USA.

Received: 21 December 2015 Accepted: 21 December 2015 Published online: 11 January 2016

Reference
1. Gravina G, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer. 2015;15:941.